Design Therapeutics (NASDAQ:DSGN) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Design Therapeutics (NASDAQ:DSGN) posted its earnings results on Wednesday. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06, FiscalAI reports.

Design Therapeutics Price Performance

Shares of NASDAQ:DSGN traded up $0.29 during midday trading on Wednesday, hitting $10.63. The company had a trading volume of 314,980 shares, compared to its average volume of 441,931. Design Therapeutics has a 12-month low of $6.23 and a 12-month high of $17.25. The company has a fifty day moving average of $12.36 and a two-hundred day moving average of $12.14. The company has a market cap of $665.23 million, a price-to-earnings ratio of -9.01 and a beta of 1.73.

Analyst Upgrades and Downgrades

DSGN has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Design Therapeutics in a report on Thursday, October 15th. Wells Fargo & Company began coverage on Design Therapeutics in a research note on Friday, October 2nd. They issued an “overweight” rating and a $26.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $17.86.

About Design Therapeutics

Design Therapeutics, Inc (NASDAQ: DSGN) is a clinical-stage biotechnology company developing small-molecule medicines for genetic diseases caused by nucleotide repeat expansions. The company’s GeneTAC, or gene-targeted activation compound, platform is designed to reactivate genes that have been silenced by these repeat expansions, with the goal of restoring production of beneficial proteins.

The company’s research has focused on disorders affecting the nervous system, muscles and eyes.